<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03582774</url>
  </required_header>
  <id_info>
    <org_study_id>18-000484</org_study_id>
    <secondary_id>NCI-2018-01518</secondary_id>
    <secondary_id>NUC MED 18-000484</secondary_id>
    <secondary_id>18-000484</secondary_id>
    <secondary_id>P30CA016042</secondary_id>
    <nct_id>NCT03582774</nct_id>
  </id_info>
  <brief_title>Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy</brief_title>
  <acronym>PSMA SRT</acronym>
  <official_title>Phase III Randomized Multicenter Trial of 68Ga-PSMA-11 PET/CT Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning [PSMA-SRT]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase III trial studies how well Gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) positron&#xD;
      emission tomography (PET)/computed tomography (CT) works in diagnosing participants with&#xD;
      prostate cancer that has come back after surgery. 68Ga-PSMA-11 are taken up by cancer cells.&#xD;
      Diagnostic procedures, such as PET/CT scans, may help find and diagnose prostate cancer and&#xD;
      find out how far the disease has spread. Giving 68Ga-PSMA-11 with PET/CT may help doctors&#xD;
      plan better for salvage radiation therapy in participants with recurrent prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. Success rate of salvage radiation therapy (SRT) measured as biochemical progression-free&#xD;
      survival after initiation of SRT.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Sub-group analysis of the primary endpoint (success rate of SRT) within the subgroup with&#xD;
      baseline PSA â‰¥ 0.5 ng/ml II. 5-year biochemical progression-free survival rate (from date of&#xD;
      randomization).&#xD;
&#xD;
      III. Metastasis free survival. IV. Initiation of additional salvage therapy after completion&#xD;
      of SRT. V. Change in initial treatment intent.&#xD;
&#xD;
      OUTLINE: Participants are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Participants receive standard of care SRT.&#xD;
&#xD;
      ARM II: Participants receive 68Ga-PSMA-11 intravenously (IV) and 50-100 minutes later undergo&#xD;
      whole-body (skull base to mid-thighs) PET/CT. Participants then undergo SRT per the&#xD;
      discretion of the treating radiation oncologist.&#xD;
&#xD;
      After conclusion of PET/CT, participants are followed up periodically for up to 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 12, 2018</start_date>
  <completion_date type="Anticipated">July 12, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 12, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success rate of salvage radiation therapy (SRT)</measure>
    <time_frame>From date of initiation of SRT assessed up to 5 years</time_frame>
    <description>Will be measured as biochemical progression-free survival after initiation of SRT. Will use a log rank test to compare progression free survival time between the two randomized treatment arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical progression-free survival rate</measure>
    <time_frame>From date of randomization assessed up to 5 years</time_frame>
    <description>Will utilize Cox-proportional hazards regression models. These models will include terms for treatment as well as appropriate clinical/demographic covariates (e.g., androgen deprivation therapy [ADT], pelvic lymph node radiation therapy [LN RT], prostate specific antigen [PSA] doubling time, Gleason grade, T stage, age, etc). Residual analyses will be performed to evaluate the proportional hazards assumptions of the Cox model. As a sensitivity analysis, we will also consider survival models that can account for competing risks (ex. death from other causes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis free survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will utilize Cox-proportional hazards regression models. These models will include terms for treatment as well as appropriate clinical/demographic covariates (e.g., ADT, pelvic LN RT, PSA doubling time, Gleason grade, T stage, age, etc). Residual analyses will be performed to evaluate the proportional hazards assumptions of the Cox model. As a sensitivity analysis, we will also consider survival models that can account for competing risks (ex. death from other causes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initiation of additional salvage therapy after completion of SRT</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will utilize Cox-proportional hazards regression models. These models will include terms for treatment as well as appropriate clinical/demographic covariates (e.g., ADT, pelvic LN RT, PSA doubling time, Gleason grade, T stage, age, etc). Residual analyses will be performed to evaluate the proportional hazards assumptions of the Cox model. As a sensitivity analysis, we will also consider survival models that can account for competing risks (ex. death from other causes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in initial treatment intent</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will utilize Cox-proportional hazards regression models. These models will include terms for treatment as well as appropriate clinical/demographic covariates (e.g., ADT, pelvic LN RT, PSA doubling time, Gleason grade, T stage, age, etc). Residual analyses will be performed to evaluate the proportional hazards assumptions of the Cox model. As a sensitivity analysis, we will also consider survival models that can account for competing risks (ex. death from other causes).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">193</enrollment>
  <condition>Recurrent Prostate Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive standard of care SRT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (68Ga-PSMA-11 PET/CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 68Ga-PSMA-11 IV and 50-100 minutes later undergo whole-body (skull base to mid-thighs) PET/CT. Participants then undergo SRT per the discretion of the treating radiation oncologist.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Practice</intervention_name>
    <description>Undergo standard of care</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <other_name>standard of care</other_name>
    <other_name>standard therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo PET/CT</description>
    <arm_group_label>Arm II (68Ga-PSMA-11 PET/CT)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>Computerized Tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT Scan</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Gallium Ga 68-labeled PSMA-11</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (68Ga-PSMA-11 PET/CT)</arm_group_label>
    <other_name>(68)Ga labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Ga-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Gallium-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68Ga)Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>68Ga-DKFZ-PSMA-11</other_name>
    <other_name>68Ga-HBED-CC-PSMA</other_name>
    <other_name>68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>68Ga-PSMA</other_name>
    <other_name>68Ga-PSMA-11</other_name>
    <other_name>68Ga-PSMA-HBED-CC</other_name>
    <other_name>[68Ga] Prostate-specific Membrane Antigen 11</other_name>
    <other_name>[68Ga]GaPSMA-11</other_name>
    <other_name>Ga PSMA</other_name>
    <other_name>Ga-68 labeled DKFZ-PSMA-11</other_name>
    <other_name>Ga-68 labeled PSMA-11</other_name>
    <other_name>Gallium Ga 68 PSMA-11</other_name>
    <other_name>Gallium-68 PSMA</other_name>
    <other_name>Gallium-68 PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>GaPSMA</other_name>
    <other_name>PSMA-HBED-CC GA-68</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET/CT</description>
    <arm_group_label>Arm II (68Ga-PSMA-11 PET/CT)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histopathology proven prostate cancer.&#xD;
&#xD;
          -  Planned SRT for recurrence after primary prostatectomy.&#xD;
&#xD;
          -  Prostate-specific antigen (PSA) &gt;= 0.1 ng/ml at time of enrollment.&#xD;
&#xD;
          -  Willingness to undergo radiotherapy.&#xD;
&#xD;
          -  Treating radiation oncologist intends to incorporate 68Ga-PSMA-11 PET/CT findings into&#xD;
             the radiotherapy plan if patient undergoes 68Ga-PSMA-11 PET/CT.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Extra-pelvic metastasis on any imaging or biopsy.&#xD;
&#xD;
          -  Androgen deprivation therapy (ADT) within 3 months before 68Ga-PSMA-11 PET/CT.&#xD;
&#xD;
          -  Contraindications to radiotherapy (including active inflammatory bowel disease).&#xD;
&#xD;
          -  Concurrent systemic therapy for prostate cancer with investigational agents.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremie Calais</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA / Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA / Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Mount Zion</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 19, 2018</study_first_submitted>
  <study_first_submitted_qc>June 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2018</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PSMA</keyword>
  <keyword>PET/CT</keyword>
  <keyword>salvage radiation therapy</keyword>
  <keyword>randomized trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edetic Acid</mesh_term>
    <mesh_term>Gallium 68 PSMA-11</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

